Wang L S, Chen E H, Zhou X J
Zhonghua Nei Ke Za Zhi. 1989 Jun;28(6):356-9, 382.
Twenty cases of primary nephrotic syndrome were treated with urokinase at a dosage of 60,000 units per day for two successive weeks. The results showed that after treatment the concentrations of fibrinogen, urine FDP, alpha 2-plasma inhibitor and plasminogen were significantly decreased (P value less than 0.01, less than 0.01, less than 0.001, less than 0.005 respectively). The concentration of antithrombin III was significantly increased (P less than 0.05). It is suggested that the treatment obviously increased the fibrinolytic activity and improved the hypercoagulated state. The clinical data showed that in addition to decrease of proteinuria and obvious increase of urine volume, the clinical manifestations and laboratory parameters showed no significant difference. Further study on the dosage and indications of urokinase is needed and the activity of coagulation and fibrinolysis in patients with deep vein thrombosis of lower extremities was also discussed.
20例原发性肾病综合征患者接受尿激酶治疗，剂量为每日60000单位，连续治疗两周。结果显示，治疗后纤维蛋白原、尿FDP、α2 -血浆抑制物和纤溶酶原浓度显著降低（P值分别小于0.01、小于0.01、小于0.001、小于0.005）。抗凝血酶III浓度显著升高（P小于0.05）。提示该治疗明显提高了纤溶活性，改善了高凝状态。临床资料显示，除蛋白尿减少和尿量明显增加外，临床表现和实验室参数无显著差异。需要进一步研究尿激酶的剂量和适应证，同时也讨论了下肢深静脉血栓形成患者的凝血和纤溶活性。
